Menu
Search
|

Menu

Close
X

Fortress Biotech Inc FBIO.OQ (NASDAQ Stock Exchange Capital Market)

4.03 USD
+0.22 (+5.77%)
As of Feb 23
chart
Previous Close 3.81
Open 3.85
Volume 70,441
3m Avg Volume 33,149
Today’s High 4.08
Today’s Low 3.85
52 Week High 5.11
52 Week Low 2.85
Shares Outstanding (mil) 50.53
Market Capitalization (mil) 238.49
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
142
FY16
16
FY15
1
EPS (USD)
FY17
-1.391
FY16
-1.378
FY15
-1.236
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.19
5.77
Price to Book (MRQ)
vs sector
3.30
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
64.97
16.52
LT Debt to Equity (MRQ)
vs sector
56.37
12.22
Return on Investment (TTM)
vs sector
-84.71
14.43
Return on Equity (TTM)
vs sector
-111.07
16.13

EXECUTIVE LEADERSHIP

Lindsay Rosenwald
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $29,254.00
Bonus: --
Eric Rowinsky
Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Robyn Hunter
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Michael Weiss
Executive Vice Chairman - Strategic Development, Since 2014
Salary: $24,324.00
Bonus: --
Lucy Lu
Executive Vice President, Since 2017
Salary: $307,875.00
Bonus: $92,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1781.6524500

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

SPONSORED STORIES